SG Americas Securities LLC Grows Position in AxoGen, Inc. (NASDAQ:AXGN)

SG Americas Securities LLC lifted its stake in shares of AxoGen, Inc. (NASDAQ:AXGN) by 34.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 21,763 shares of the medical equipment provider’s stock after acquiring an additional 5,576 shares during the period. SG Americas Securities LLC’s holdings in AxoGen were worth $359,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of AXGN. JPMorgan Chase & Co. grew its position in shares of AxoGen by 2,912.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider’s stock worth $7,697,000 after acquiring an additional 530,775 shares in the last quarter. Parkman Healthcare Partners LLC acquired a new position in shares of AxoGen in the 3rd quarter worth $5,789,000. FMR LLC grew its holdings in shares of AxoGen by 743.1% in the 3rd quarter. FMR LLC now owns 178,957 shares of the medical equipment provider’s stock worth $2,509,000 after acquiring an additional 157,730 shares during the last quarter. Eagle Asset Management Inc. purchased a new position in shares of AxoGen during the third quarter valued at $1,728,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of AxoGen by 66.3% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 308,686 shares of the medical equipment provider’s stock valued at $4,328,000 after buying an additional 123,118 shares in the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Stock Down 1.6 %

NASDAQ:AXGN opened at $17.92 on Tuesday. The stock’s fifty day moving average price is $16.25 and its two-hundred day moving average price is $13.88. AxoGen, Inc. has a 52-week low of $5.55 and a 52-week high of $19.06. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74. The company has a market cap of $788.66 million, a price-to-earnings ratio of -56.00 and a beta of 1.00.

Analyst Ratings Changes

AXGN has been the subject of a number of analyst reports. Canaccord Genuity Group boosted their price target on AxoGen from $18.00 to $22.00 and gave the stock a “buy” rating in a research report on Monday. StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a research note on Tuesday, October 15th.

AxoGen Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.